IGF-1 DES
A truncated form of IGF-1 missing the first 3 amino acids, with 10x greater potency and very short half-life for localized effects.
What is IGF-1 DES?
IGF-1 DES (Des 1-3 IGF-1) is a naturally occurring truncated form of IGF-1 found in the brain and other tissues. Missing the first three amino acids, it has virtually no binding to IGFBPs, making it approximately 10x more potent than native IGF-1 at the receptor. Its very short half-life (~20-30 minutes) makes it useful for localized, site-specific effects.
What IGF-1 DES Is Investigated For
IGF-1 DES is used almost exclusively in the bodybuilding and research-chemical space for site-specific muscle growth at the injection site, with the short half-life and ~10x IGFBP-independent potency at IGF-1R providing the rationale for its 'localized' positioning. The strongest evidence is biochemical — near-complete loss of IGFBP binding is well-characterized, and IGF-1R signaling (PI3K/Akt/mTOR, Ras/MAPK) is one of the best-understood growth factor pathways. Beyond that, the human evidence is essentially absent: no clinical trials for any indication, no dose-response data, and no human imaging work to validate the central 'differential local hypertrophy' claim. Community dosing (20–75 mcg IM per site) rests on rodent extrapolation, and the research-chemical supply chain has documented issues with DES, LR3, and native IGF-1 being mislabeled for each other. DES is meaningfully safer than LR3 on glucose-lowering duration, but 'localized' does not mean 'systemically inactive.'
History & Discovery
Des(1-3) IGF-1 — the 'DES' in the common name refers to the deletion of the first three N-terminal amino acids Gly-Pro-Glu — was first identified as a naturally occurring IGF-1 variant isolated from bovine colostrum and later detected in the human central nervous system. The tripeptide Gly-Pro-Glu that is cleaved off is itself neuroactive, and early neuroscience work by groups including Peter Gluckman in New Zealand characterized both the parent truncated peptide and the released N-terminal fragment as bioactive in their own right. The DES variant's key pharmacologic property, characterized across multiple groups including the Ballard/CSIRO program in Adelaide and aligning with the broader IGF-1 biology program of Derek Le Roith, is roughly an order-of-magnitude greater potency at IGF-1R compared with native IGF-1, attributable almost entirely to near-complete loss of IGFBP binding. Synthetic DES IGF-1 followed native-identification into the research-reagent market in the 1990s as a cell-culture tool and into whole-animal studies of localized versus systemic IGF-1 signaling. Unlike IGF-1 LR3, DES was never engineered as a long-acting depot — the short half-life (tens of minutes) is intrinsic to the truncation. Bodybuilding-market adoption arrived in the 2000s with the specific positioning as a 'site-injection' peptide for localized muscle growth, in contrast with LR3's systemic anabolic framing. Human therapeutic development never occurred.
How It Works
IGF-1 DES is a concentrated, fast-acting version of the body's growth signal. Because it works so quickly and locally, it can target specific muscles when injected directly into them.
Des(1-3) IGF-1 lacks the N-terminal tripeptide (Gly-Pro-Glu) that mediates IGFBP binding. This results in near-complete bioavailability at the IGF-1R. The same PI3K/Akt/mTOR and Ras/MAPK signaling cascades are activated but with greater intensity due to higher free peptide concentration. The rapid clearance limits systemic exposure, making it suitable for localized intramuscular administration targeting satellite cell activation.
Evidence Snapshot
Human Clinical Evidence
Very limited. Primarily used in research and bodybuilding contexts.
Animal / Preclinical
Moderate. Des(1-3) IGF-1 biology characterized in cell culture and animal models.
Mechanistic Rationale
Strong. IGF-1R signaling well-understood; IGFBP-independent activity is established.
Research Gaps & Open Questions
What the current literature has not yet settled about IGF-1 DES:
- 01No human clinical trials of DES IGF-1 for any indication — all human exposure is off-label via research-chemical channels without systematic safety surveillance.
- 02Actual site-specificity in humans — the 'localized growth' claim central to DES's market positioning rests on the short half-life, but quantitative data on how much local versus systemic IGF-1R activation a typical IM dose produces in humans is absent.
- 03Long-term local tissue effects — repeated IM injection of a mitogenic peptide into the same muscle is biologically plausible to induce fibrosis, chronic low-grade inflammation, or fibroblast dysregulation; no systematic imaging or histologic human study exists.
- 04Dose-response for hypertrophy versus adverse effects — the 20–75 mcg community range is not anchored in any human dose-ranging study; minimum effective and maximum tolerated doses are uncharacterized.
- 05Cancer-risk impact of episodic supraphysiologic IGF-1R activation — the epidemiology linking IGF-1 to cancer is chronic-exposure data, and the implications of repeated short pulses in muscle tissue are unquantified.
- 06Supply-chain integrity — DES, LR3, and native IGF-1 are mislabeled across the research-chemical market; identity and purity assurance is not pharmaceutical-grade.
Forms & Administration
IM injection directly into target muscle. Typical research doses: 50-100mcg per site, pre or post-workout. Very short half-life requires precise timing. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Community protocols most commonly describe 20–75 mcg per site-specific intramuscular injection, with 50 mcg a frequently cited middle-of-the-range starting point. These figures are community convention, not clinical evidence — no human dose-ranging study of DES IGF-1 has been conducted. The short half-life means the per-dose figure largely determines local exposure; systemic accumulation is minimal.
Frequency
Pre- or immediately post-workout IM injection into the trained muscle group is the most commonly described cadence, often on training days only. Some users rotate site-by-site across training sessions. Because of the short half-life, skipping rest days is routine in community protocols — there is no depot to carry effects forward.
Timing Considerations
Time of day
Ties to training schedule rather than clock time.
Relative to meals
Often paired with a post-workout protein-and-carbohydrate meal to ride endogenous insulin and amplify the myogenic effect.
Relative to exercise
Injected pre- or immediately post-workout, intramuscular into the trained muscle group. DES has a very short half-life and a largely local mechanism, so injection-site locality matters more than with systemic IGF-1-LR3.
Cycle Length
Typical described runs are 4–6 weeks on, followed by a comparable time off. Rationale mirrors LR3 concerns — IGF-1R signaling fatigue, theoretical mitogenic risk with chronic supraphysiologic exposure — though the localized and short-acting character of DES makes the risk argument less acute than for LR3. The 4–6 week convention is not derived from human data.
Protocol Notes
DES is supplied as a lyophilized powder reconstituted in bacteriostatic water. The practical injection target is intramuscular into the belly of the trained muscle using a small-gauge (typically 29–31g) insulin syringe; the explicit goal is local IGF-1R activation at the site of mechanical loading rather than systemic anabolism. Hypoglycemia risk is lower than with LR3 because of the short exposure window, but not zero — larger doses or accidental vascular injection can still produce measurable glucose lowering. Repeated injection into the same muscle site is a meaningful practical concern: community reports describe local scarring, fibrotic palpable changes, and occasionally sterile abscess formation when technique, rotation, and peptide purity are poor. As with LR3, the research-chemical supply chain means purity, correct peptide identity, and endotoxin content are not assured. Product that is actually native IGF-1 or LR3 mislabeled as DES is a documented market issue and changes the risk picture materially.
These numbers describe community practice, not a prescription. IGF-1 DES is not FDA-approved for any indication. Site-specific intramuscular injection carries local tissue and infection risks independent of the peptide itself. Any actual use should be under the direct supervision of a qualified healthcare provider.
Timeline of Effects
Onset
Local effects at the injection site — increased pump, fullness, reported enhanced recovery of that specific muscle — are typically described within the first 1–2 training sessions after introducing the peptide. These reports are anecdotal; no human study has objectively characterized onset.
Peak Effect
Visible local hypertrophy effects are most often described in the 3–6 week window of consistent protocol use, aligning with the typical muscle-hypertrophy adaptation timeframe rather than pharmacologic accumulation. The short half-life of DES means there is no depot peak in the conventional sense — peak local IGF-1R activation occurs within an hour of injection.
After Discontinuation
Because DES clears within hours, there is no extended pharmacologic tail after the last dose. Muscle adaptations accrued during the protocol persist under continued training and nutrition, but no subsequent injections means no subsequent supraphysiologic IGF-1R stimulation. Some users report a perceived loss of the 'full' feeling at previously targeted sites after cessation, consistent with loss of acute local IGF-1 tone.
Common Questions
Who IGF-1 DES Is NOT For
- •Active or recent-history cancer, particularly hormone-sensitive malignancies — localized administration does not eliminate the IGF-1R activation concern, and any residual systemic exposure still carries mitogenic risk.
- •Diabetes or impaired glucose regulation — even with the short half-life, acute glucose lowering can occur at higher doses and compound insulin or secretagogue effects.
- •Pregnancy and breastfeeding — no safety data; IGF-1 is central to fetal growth regulation.
- •Pediatric use (under 18) — no appropriate indication, and growth-plate and developmental considerations apply.
- •Active acromegaly or untreated pituitary tumor — any exogenous IGF-1R agonism is contraindicated.
- •Local injection-site contraindications — active infection, significant scar tissue, or bleeding disorder at the planned injection site.
Drug & Supplement Interactions
Interaction data specific to DES is absent; extrapolation from IGF-1 pharmacology applies in muted form given the short systemic half-life. Insulin, sulfonylureas, meglitinides, and other glucose-lowering agents remain the most clinically meaningful interaction — compound hypoglycemia is possible, particularly at higher DES doses, even if the risk window is narrower than with LR3. Patients on diabetes medications should not use DES without clinician oversight. Concurrent use with growth hormone, GH secretagogues (tesamorelin, sermorelin, CJC-1295, ipamorelin), or MK-677 potentiates systemic IGF-1R activation beyond what DES alone produces, eroding any claimed 'localized' risk advantage. Anabolic-androgenic steroids do not directly interact with IGF-1R but share the cardiovascular- and cancer-risk profile. Oncology patients — particularly those on IGF-1R-targeting agents — should not use DES. Corticosteroids may blunt local anabolic response.
Safety Profile
Common Side Effects
Cautions
- • Not FDA-approved
- • Very limited human safety data
- • Theoretical cancer risk
- • Must be injected site-specifically
What We Don't Know
Human safety profile is poorly characterized. Most data extrapolated from IGF-1 biology.
Legal Status
United States
IGF-1 DES is not FDA-approved for any medical indication. It sits in the same regulatory category as LR3: a non-approved analogue distinct from mecasermin (Increlex), sold through research-chemical channels labeled 'not for human use.' Distribution for human consumption is unauthorized under the FD&C Act. It is not a scheduled controlled substance.
International
Not authorized as a medicine in the EU, UK, Canada, or Australia. Australian TGA treats it as a Schedule 4 prescription-only substance. Importation for personal use is restricted or prohibited in most developed regulatory regimes.
Sports & Competition
Prohibited at all times under WADA category S2 as an IGF-1 analogue and mimetic. Athletes subject to WADA, USADA, UKAD, or equivalent code frameworks should consider DES categorically prohibited in and out of competition. Site-specific intramuscular injection does not change its prohibited status.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
IGF-1 DES only works locally, so it carries no systemic risk.
Reality
The short half-life reduces systemic exposure compared with LR3, but it does not eliminate it. Some fraction of each dose enters systemic circulation and briefly activates IGF-1R across tissues. 'Local-only' is a reasonable approximation for the dominant effect, not a guarantee of zero systemic activity.
Myth
Site-injection DES builds muscle where you inject it, like a targeted spot-grower.
Reality
There is a plausible mechanistic basis for enhanced local satellite cell activation at the injection site, but robust human imaging evidence of differential hypertrophy between injected and non-injected muscles is not established. Hypertrophy still requires training, mechanical load, and systemic nutrition; the peptide does not override those requirements.
Myth
Because DES is naturally occurring in the body, it is safer than LR3.
Reality
DES is found endogenously at trace concentrations in specific tissues. Injecting 50 mcg into a muscle produces a supraphysiologic local concentration not seen in normal physiology. 'Naturally occurring' at nanogram levels is not the same as 'naturally occurring' at the pharmacologic doses used in injection protocols.
Myth
DES avoids the hypoglycemia risk entirely.
Reality
DES produces less and shorter-duration glucose lowering than LR3, but measurable acute hypoglycemia can still occur, particularly at higher doses, with inadvertent vascular administration, or in combination with insulin or insulin secretagogues. Treating DES as having zero glucose-lowering effect is inaccurate.
Published Research
7 studiesDes(1-3)IGF-1 treatment normalizes type 1 IGF receptor and phospho-Akt (Thr 308) immunoreactivity in predegenerative retina of diabetic rats
IGF-I has a dual effect on insulin release from isolated, perifused adult rat islets of Langerhans
The effects of insulin-like growth factor (IGF)-1, IGF-2, and des-IGF-1 on neuronal loss after hypoxic-ischemic brain injury in adult rats: evidence for a role for IGF binding proteins
Effects of IGF-1, truncated IGF-1 and the tripeptide Gly-Pro-Glu on acetylcholine release from parietal cortex of rat brain
A key functional role for the insulin-like growth factor 1 N-terminal pentapeptide
Insulin-like growth factor (IGF)-binding proteins inhibit the biological activities of IGF-1 and IGF-2 but not des-(1-3)-IGF-1
Truncated IGF-1 exerts trophic effects on fetal brain tissue grafts
Quick Facts
- Class
- Growth Factor Analogue
- Tier
- D
- Evidence
- Emerging
- Safety
- Limited Data
- Updated
- Mar 2026
- Citations
- 7PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.